Home   About this service   Get the news  
+32 2 743 34 03

 Belgium  Other Countries
Page : 1 - 2 - ... 6 - 7 - 8 - 9 - 10 - 11 - 12 - ...
UCB [BE0003739530/UCB]   
[26/07/2018]

UCB : UCB Media Room: Half Year Results 2018

UCB Half Year Report 2018:UCB continues its growth pathBrussels Belgium, 26 July 2018 – 7:00 CEST – regulated information –Revenue reached € 2.27 billion: 2%, 6% CER;net sales increased to € 2.15 billion: 5%, 10% CER.Underlying profitability rEBITDA increased to € 794 million: 7%, 12% CERR&D update: romosozumab resubmission in the U.S.Financial outlook for 2018 confirmed: Revenue... See more
 
UCB [BE0003739530/UCB]   
[24/07/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.2 notifications referring to situation on 18 July and 19 July 2018Threshold crossed: 5%Latest holding: 5.00%Brussels Belgium, 24 July 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency... See more
 
UCB [BE0003739530/UCB]   
[13/07/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notificationBrussels Belgium, 13 July 2018 – 20:00 CEST – regulated information1. Summary of the notificationPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification dated 9 July 2018 from BlackRock, Inc. having its registered office at 55 East 52nd Street, New York, NY, 10055,... See more
 
UCB [BE0003739530/UCB]   
[13/07/2018]

UCB : UCB Media Room: BLA Resubmission for Evenity to US FDA

UCB and Amgen Resubmit Biologics Licence Application BLA for EVENITYTM Romosozumab to the U.S. FDABLA Includes Data From Pivotal Phase 3 Studies of More Than 11,000 PatientsBrussels, Belgium and Thousand Oaks, CalifJuly 13, 2018, 07:00 CET – UCB Euronext Brussels: UCB and Amgen NASDAQ:AMGN today announced the resubmission of the Biologics License Application BLA to the U.S. Food and Drug... See more
 
UCB [BE0003739530/UCB]   
[06/07/2018]

UCB : UCB Media Room: Transparency Notification

Transparency notifications BlackRock, Inc.2 notifications referring to situation on 29 June and 2 July 2018Threshold crossed: 5%Latest shareholding: 4,91%Brussels Belgium, 6 July 2018 – 20:00 CEST – regulated information1. Summary of the notificationsPursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2... See more
 
UCB [BE0003739530/UCB]   
[02/07/2018]

UCB : UCB Media Room: Neupro Approval in China

UCB announces approval of NEUPRO® in China to treat Parkinson’s DiseaseNEUPRO now approved in China for the treatment of the signs and symptoms of earlystage idiopathic Parkinson’s Disease as monotherapy i.e. without levodopa or in combination with levodopaNEUPRO approval in China reinforces UCB’s ongoing commitment to supporting patient value across China and to offering Chinese patients... See more